Form 4: Veracyte CEO Sells Shares, Tax Withholding Reported

Veracyte CEO Marc Stapley reported the sale of 7,668 shares and the withholding of 7,914 shares for tax obligations, all under a pre-arranged 10b5-1 plan.

Summary

• Marc Stapley, Veracyte, Inc.'s Chief Executive Officer and a Director, reported transactions involving the company's common stock.
• On December 2, 2025, 7,914 shares of common stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. This was not a sale.
• The shares withheld were valued at $46.16 per share.
• Following this transaction, Marc Stapley beneficially owned 326,271 shares of common stock.
• On December 4, 2025, Marc Stapley sold 4,448 shares of common stock at a weighted average price of $46.9005 per share, with individual sale prices ranging from $46.22 to $47.21.
• Also on December 4, 2025, an additional 3,220 shares of common stock were sold at a weighted average price of $47.3485 per share, with individual sale prices ranging from $47.23 to $47.49.
• Both sales on December 4, 2025, totaling 7,668 shares, were executed pursuant to a Rule 10b5-1 plan adopted by Marc Stapley on September 13, 2024.
• After all reported transactions, Marc Stapley beneficially owned 318,603 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including tax-related share withholding and pre-planned sales under a 10b5-1 plan, which are standard for executives and do not inherently indicate a positive or negative shift in company fundamentals.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, adopted on September 13, 2024, which indicates planned transactions rather than opportunistic selling based on non-public information.
• Tax withholding for restricted stock unit vesting is a routine and expected event for executive compensation.

Negatives

• Marc Stapley, a key executive and director, disposed of a total of 7,668 shares through sales.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024.

Industry Context

Insider transaction reports (Form 4s) are routine disclosures for publicly traded companies. The use of a Rule 10b5-1 plan for stock sales is a common practice among executives to manage their equity holdings and avoid accusations of trading on material non-public information, aligning with corporate governance best practices in the industry.

Stakeholder Impact

• Shareholders may note the disposition of shares by a key executive, but the pre-arranged nature of the sales under a 10b5-1 plan typically mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The Form 4 details routine insider transactions, including tax-related share withholding and pre-scheduled sales under a 10b5-1 plan. These transactions are common for executives and do not inherently signal a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this filing.

Keywords

Veracyte, VCYT, Marc Stapley, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Tax Withholding